This country profile provides an overview of Mali’s progress in reaching those in need of mass NTD treatment based on 2019 data.
*This includes all countries in Africa that are endemic for at least one of the five NTDs
In 2019, insecurity in the north of Mali prevented TAS1 and MDA being conducted for elephantiasis (lymphatic filariasis), which resulted in a low 2019 index score. In 2020, Mali’s NTD programme successfully conducted the relevant surveys and Mali’s score is expected to increase.
Treatment coverage decreased from 69% in 2018 to 0% in 2019.
Mali is conducting post-preventive chemotherapy surveillance.
Mali does not require mass treatment for intestinal worms.
Treatment coverage increased from 91% in 2018 to 95% in 2019.
Treatment coverage increased from 77% in 2018 to 79% in 2019.